Annapolis, MD area dermatologist offers Lutronic Infini skin treatment
Scars are a common concern for patients who visit the Center for Dermatology and Dermatologic Surgery. Dr. Cheryl Burgess and her staff are dedicated to helping patients improve their skin’s texture and tone, boosting self-confidence. When scars are present, solutions are discussed with Annapolis, MD area patients. One solution is Lutronic Infini treatment.

What is Lutronic Infini?
Lutronic Infini is a high intensity focused radiofrequency system that is used by our practice for scar revision. This treatment is:
- Safe for all skin types
- Low in risks and side effects
- Delivered with microneedles for improved comfort and result
- Customizable for a patient’s specific needs
- Adjustable in aggression
- Available in two different modes of treatment for deep or superficial treatments
What types of scars can be treated with Lutronic Infini services?
Most patients use radiofrequency treatments for addressing acne scars on the facial area. However, it can also be used to treat scars that develop due to injuries or surgeries. Determining if Lutronic Infini treatments is right for a patient is achieved during a consultation appointment. Dr. Cheryl Burgess may suggest this or alternative services such as dermal fillers or microdermabrasion. Discussing options with a professional is the best way to choose effective solutions.
How does RF treatment work?
By administering radiofrequency energy into the skin, it helps stimulate the body’s natural ability to produce collagen and elastin. This encourages the body to naturally heal itself and remodel the scars. Some patients will see results after just one treatment, while others may need to undergo several sessions to reduce the appearance of a scar.
Learn more today about scar revision with Lutronic Infini
Call our state-of-the-art facility in Annapolis, MD today at (202) 955 - 5757 to schedule an appointment. Her practice is located at 167-W Jennifer Road, with another location in Washington, DC.
Share this Article
Back to Home Page